Why drug combinations are the future of treatment in CLL

Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses drug combinations for the treatment of chronic lymphocytic leukemia (CLL). In particular, Dr Ghia talks about the combination of ibrutinib and venetoclax, as well as ibrutinib and venetoclax in combination with obinutuzumab (GA-101) (NCT02758665).
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video